{"organizations": [], "uuid": "9e82a97406cf5df4dff307998af2a3bb86300765", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-issues-warning-letter-to-becto/brief-fda-issues-warning-letter-to-becton-dickinson-co-idUSFWN1P60VT", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-11T20:37:00.000+02:00", "replies_count": 0, "uuid": "9e82a97406cf5df4dff307998af2a3bb86300765"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-issues-warning-letter-to-becto/brief-fda-issues-warning-letter-to-becton-dickinson-co-idUSFWN1P60VT", "ord_in_thread": 0, "title": "BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co", "locations": [], "entities": {"persons": [{"name": "becton dickinson", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-fda issues warning letter to becton dickinson & co", "sentiment": "negative"}, {"name": "becton dickinson & co", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "magellan", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 11, 2018 / 6:38 PM / Updated 35 minutes ago BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co Reuters Staff 1 Min Read \nJan 11 (Reuters) - U.S. Food and Drug Administration: \n* FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES‍​ \n* U.S. FDA SAYS BECTON DICKINSON‘S VIOLATIONS INCLUDE MARKETING MODIFIED VERSIONS OF CERTAIN BD VACUTAINER BLOOD COLLECTION TUBES WITHOUT REQUIRED APPROVAL \n* FDA SAYS INSPECTION SHOWED BD VIOLATED LAW BY MAKING SIGNIFICANT CHANGE TO SOME OF ITS DEVICES WITHOUT NOTIFYING FDA \n* ‍FDA​ SAYS VIOLATIONS WERE DISCOVERED THROUGH AN INSPECTION OF BECTON DICKINSON ’S NEW JERSEY FACILITY \n* FDA SAYS BECTON DICKINSON HAS UNTIL FEB 1, 2018 TO NOTIFY FDA ABOUT SPECIFIC STEPS CO HAS TAKEN TO ADDRESS FDA IDENTIFIED VIOLATIONS \n* FDA - BD DID NOT ADDRESS COMPLAINT OF VARIABILITY IN RESULTS WHEN SOME BD VACUTAINER BLOOD COLLECTION TUBES WERE USED WITH MAGELLAN DIAGNOSTICS’ LEADCARE TEST SYSTEMS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-11T20:37:00.000+02:00", "crawled": "2018-01-11T21:03:15.022+02:00", "highlightTitle": ""}